Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 625,783 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 625,783 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $34.00, for a total transaction of $21,276,622.00. Following the sale, the director owned 14,501,546 shares in the company, valued at $493,052,564. This represents a 4.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Daniel Allen Gold also recently made the following trade(s):

• On Tuesday, June 30th, Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock. The shares were sold at an average price of $35.28, for a total value of $436,766.40.
• On Monday, June 29th, Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock. The shares were sold at an average price of $34.55, for a total transaction of $27,640,000.00.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $35.39 on Wednesday. Roivant Sciences Ltd. has a 1-year low of $10.70 and a 1-year high of $35.90. The firm has a market capitalization of $25.45 billion, a P/E ratio of -58.98 and a beta of 1.13. The company’s 50-day moving average is $29.88 and its 200 day moving average is $27.02.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The business had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. During the same period last year, the company earned ($0.29) earnings per share. Research analysts anticipate that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ROIV has been the subject of a number of analyst reports. TD Cowen upped their target price on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of Roivant Sciences in a research report on Thursday, May 21st. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Citigroup boosted their target price on shares of Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Finally, Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.59.

Institutional Trading of Roivant Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. grew its stake in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares during the last quarter. Allworth Financial LP raised its stake in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Roivant Sciences during the fourth quarter worth about $47,000. Finally, Bessemer Group Inc. boosted its position in Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after buying an additional 441 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.